Descrizione del progetto
Nuovo vaccino universale contro i focolai di influenza stagionale
L’influenza stagionale e altre infezioni virali respiratorie da RNA colpiscono circa il 10 % della popolazione mondiale ogni anno. La vaccinazione profilattica esistente ha un’efficacia limitata e richiede aggiornamenti per ogni stagione influenzale o crisi pandemica a causa dell’elevato tasso di mutazione delle proteine di superficie virali bersaglio dei vaccini attuali. La biotecnologia francese in ambito clinico OSIVAX si propone di sviluppare nuovi vaccini per prevenire le infezioni virali respiratorie per più stagioni e focolai. OSIVAX ha sviluppato OVX836, un vaccino candidato antinfluenzale universale basato su una tecnologia proprietaria di potenziamento immunitario che innesca risposte immunitarie mirate e durevoli. OVX836 aggira gli aggiornamenti vaccinali annuali intervenendo su una proteina intravirale conservata in tutti i ceppi influenzali. L’obiettivo del progetto OSIRIX, finanziato dall’UE, è di preparare OVX836 per il traguardo della prova clinica di efficacia.
Obiettivo
While an ongoing pandemic outbreak of coronavirus (COVID-19) is having enormous impact on global societies, a quest for effective vaccination becomes of unprecedented importance to save lives and economies globally.
Symptomatic flu, another respiratory RNA viral infection, affects ~10% of global population every year and leads to regular pandemic outbreaks. Existing prophylactic vaccination requires updates each flu season or pandemic outbreak, and has a strikingly limited efficacy (40% on average, as low as 9% in elderly). This is mainly due to a rapid mutation rate of surface viral proteins that are targeted by the current vaccines. Governments, institutions and vaccine community urgently seek for a universal flu vaccine that would provide a multi-season protection against all seasonal and emerging pandemic viral strains.
OSIVAX, a French clinical stage innovative biotech, strives to develop vaccines able to prevent respiratory viral infections across multiple seasons and outbreak. OSIVAX has developed OVX836, a best-in-class, game-changing universal flu vaccine candidate.
OVX836 is based on oligoDOM®, a proprietary immune-boosting technology that triggers powerful, targeted and durable immune responses involving activation of specific immune response killing infected cells. OVX836 circumvents the need for annual vaccination updates by targeting an intraviral protein that is highly conserved across all influenza strains.
OVX836 has a potential to disrupt the flu vaccine market currently dominated by single-season vaccines. The revolutionary universal flu vaccine is predicted to have a blockbuster potential (>€2.5 billion). OSIVAX’s experienced team aims to get OVX836 ready for the clinical proof-of-efficacy milestone (Phase IIb) that will position the company for >€500M licensing deal with a big pharma in 2024.
At the moment, OSIVAX leverages this revolutionary clinical-stage technology to initiate the development of a universal vaccine against corona
Campo scientifico
- medical and health sciencesbasic medicineimmunologyimmunisation
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesinfluenza
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-EIC-SMEInst-2018-2020-3
Meccanismo di finanziamento
SME-2 - SME instrument phase 2Coordinatore
75008 Paris
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.